Szabados, B. E.Rodriguez-Vida, A.Duran, I.Crabb, S. J.van-der-Heijden, M. S.Pous, A. FontGravis, G.Herranz, U. AnidoProtheroe, A.Ravaud, A.Maillet, D.Mendez, M. J.Suarez, C.Linch, M.Prendergast, A.Tyson, C.Mousa, K.Castellano, D.Powles, T. B.2025-01-072025-01-072020-11-01Szabados, B. E. Rodriguez-Vida, A. Duran, I., Crabb, S. J., van-der-Heijden, M. S., Pous, A. Font et al. A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis. Ann. oncol.2020; (31);S13190923-7534https://hdl.handle.net/10668/25477Background. ABACUS is a phase II single-arm study that evaluated the safety and efficacy of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) awaiting radical cystectomy (RC). Methods. This single arm, phase II study investigated two cycles of atezolizumab (1200mg given every 3 weeks) prior to RC in MIBC(T2-4aN0M0) (NCT02662309). The study included patients who were ineligible or refused neoadjuvant cisplatin-based chemotherapy and had transitional cell histology. Pathological complete response (pCR) was the primary endpoint. Adverse events (AEs) and surgical complications were assessed using CTCAE v4.03 and the Clavien-Dindo classification.enCisplatinatezolizumabUrinary Bladder NeoplasmsMusclesHumansCystectomyNeoadjuvant Therapyconference outputRestricted AccessPacientesBrazoCisplatinoCistectomíaHistologíaNeoplasias de la vejiga urinariaCélulasQuimioterapiaReacción en cadena de la Polimerasa10.1016/j.annonc.2020.10.2111569-8041http://www.annalsofoncology.org/article/S0923753420427024/pdf600988900203